Expanding Access to a Hep C Cure

Dec 22, 2014
Express Scripts and AbbVie make a hepatitis C cure available to millions of patients in need.
Tags
  • Hepatitis C

Today, we announced an update to our National Preferred Formulary that will significantly expand access to AbbVie’s new medication, Viekira Pak®, a breakthrough treatment for hepatitis C.

Unprecedented Solution to Unprecedented Healthcare Challenge

Viekira Pak, approved by the U.S. Food and Drug Administration on December 19, was determined to be at least clinically equivalent to Harvoni® (ledipasvir and sofosbuvir) and Sovaldi® (sofosbuvir) by Express Scripts’ independent Pharmacy & Therapeutics Committee. As a result of the committee’s determination, Viekira Pak will immediately be added to the Express Scripts formulary, and will be the exclusive option for patients with genotype 1 hepatitis C, regardless of symptoms or disease progression, starting January 1, 2015.

Approximately 75% of the more than 3 million Americans with hepatitis C have a form of the virus known as genotype 1. All clinically appropriate patients with that form of hepatitis C who are covered by the Express Scripts National Preferred Formulary – which covers about 25 million Americans – will have access to Viekira Pak.

Beginning January 1, 2015, Sovaldi, Harvoni and Olysio® (simeprevir) will be excluded from the National Preferred Formulary. Sovaldi, Harvoni and Olysio will continue to be available for patients who have already begun treatment regimens. Sovaldi will be available for patients with other hepatitis C genotypes who have advanced liver disease.

Affordable Access to a Curative Hepatitis C Therapy

Express Scripts and AbbVie have a single focus: do what’s right for hepatitis C patients. For the first time, a pharmaceutical manufacturer and a pharmacy benefit manager have created an agreement to deliver on the promise of a curative therapy for hepatitis C patients. Pharmaceutical innovation must be rewarded based on the value it brings to patients and payers. This agreement marks a fundamental change in how sustainable access and affordability will be delivered to hepatitis C patients.

Unlike pricier hepatitis C medications that many U.S. payers were covering only for patients experiencing stage 3 or 4 liver disease, Viekira Pak will be available for all clinically appropriate plan members covered by the Express Scripts National Preferred Formulary.

Superior Patient Care, Greater Payer Value

Viekira Pak will be dispensed through the Accredo® Specialty Pharmacy, which delivers superior treatment outcomes and cost effectiveness compared to other specialty pharmacies. Accredo’s Hepatitis Therapeutic Resource Center® offers a team of specialist pharmacists and health professionals whose patient support model drives the industry’s highest level of successful therapy completion, a vital part of the care continuum that delivers better outcomes to patients and financial relief to payers.

We want all hepatitis C patients to receive the best care our healthcare system can deliver, but that option simply wasn’t possible until today. Our formulary approach makes specialty medications more affordable, and Accredo’s unique clinical model will enable as many patients as possible to be cured of hepatitis C.

comments powered by Disqus